Chargement Évènements

« Tous les Évènements

Conférence Ellen Donker et Alain Roussel – Generation of Nanobodies using extracellular vesicles for diagnostic purposes

| décembre 8 - 11:00 à 12:00

Generation of Nanobodies using extracellular vesicles for diagnostic purposes.

Membrane proteins (MPs) on the surface of cells are involved in many biological processes, such as cell signaling or viral infection, and play an essential role in regulating the immune response. Consequently, they account for a large majority of the markers used as therapeutic or diagnostic targets. Currently, there is an increase demand of monoclonal antibodies (Abs) in the field of immunotherapy and diagnostics with approximately 175 therapeutic Abs marketed, and at least 1200 therapeutic Abs undergoing clinical evaluation. In the meantime, the purification process of these MPs is time-consuming, random, costly and generally results in small quantities of protein, often unstable. Most importantly, the use of detergents for their extraction disturbs their native conformation because they do not stabilize membrane domains as effectively as the natural membrane lipids. For these reasons, Abs are usually generated against the soluble extracellular domains of MPs. Unfortunately, this leads to Abs that may behave differently when used on targets in their native state on the cell surface.

In response to that issue, we set up the LabCom NVDIAG, a partnership between the Host-Pathogen Interaction team from the LISM laboratory (CNRS) and the BioCytex company. We developed a technology using extracellular vesicles (EVs) expressing MPs at their surface. This reveals original epitopes that often do not exist on the soluble extracellular domains of MPs, offering the potential to develop innovative Nanobodies (Nbs) against a wide range of targets, even those known to be difficult. We especially work on the development of Nbs that are non-competitive with therapeutic Abs, which could be used in quantitative Flow Cytometry (qFC) as companion diagnostic tests for monitoring treatment, particularly in cancer immunotherapy.

In the first part of the presentation, we will introduce our technological developments regarding the generation of nanobodies using extracellular vesicles. In the second part, we will present the results obtained for the CD38 receptor, which is involved in multiple myeloma.

Pour suivre la conférence en direct, cliquez ici.

Détails

Lieu

  • Salle Cazaux